Retrieve available abstracts of 11 articles: HTML format
Single Articles
August 2025
YI X, Zimath PL, Martin-Vazquez E, Oliveira JG, et al Transcriptomics of autoimmune diseases identifies FGFR1 as a target for
pancreatic beta-cell protection.
J Autoimmun. 2025;156:103469. PubMedAbstract available
July 2025
OTT R, Singh T, Schutte-Borkovec K, Scholz M, et al Epigenetic differences at immune and type 1 diabetes susceptibility genes in
blood from young children after COVID-19 infection.
J Autoimmun. 2025;156:103468. PubMedAbstract available
June 2025
LEE YJ, Fang YW, Chen MT, Liou HH, et al Association between autoimmune diseases and glucagon-like peptide-1 receptor
agonists: A real-world evidence study.
J Autoimmun. 2025;155:103453. PubMedAbstract available
SAKSAGER AB, Hede FD, Barra C Autoimmune associated HLAs and T cell autoantigens exhibit common patterns across
several autoimmune diseases.
J Autoimmun. 2025;155:103443. PubMedAbstract available
April 2025
YANG Y, Liu W, Zhang Z, Zhang Y, et al Exploring glucagon-like peptide-1 receptor agonists as potential
disease-modifying agents in autoimmune diseases.
J Autoimmun. 2025;153:103414. PubMedAbstract available
January 2025
LI J, Xie Z, Yang L, Guo K, et al The impact of gut microbiome on immune and metabolic homeostasis in type 1
diabetes: Clinical insights for prevention and treatment strategies.
J Autoimmun. 2025;151:103371. PubMedAbstract available
AROWOSEGBE A, Guo Z, Vanderleeden E, Derr AG, et al Janus kinase inhibition prevents autoimmune diabetes in LEW.1WR1 rats.
J Autoimmun. 2025;151:103358. PubMedAbstract available
April 2024
DO JS, Arribas-Layton D, Juan J, Garcia I, et al The CD318/CD6 axis limits type 1 diabetes islet autoantigen-specific human T cell
activation.
J Autoimmun. 2024;146:103228. PubMedAbstract available
March 2024
GARCIA-LOZA I, Perna-Barrull D, Aguilera E, Almenara-Fuentes L, et al Targeting macrophages with phosphatidylserine-rich liposomes as a potential
antigen-specific immunotherapy for type 1 diabetes.
J Autoimmun. 2024;145:103196. PubMedAbstract available
October 2023
KISHIMOTO TK, Fournier M, Michaud A, Rizzo G, et al Rapamycin nanoparticles increase the therapeutic window of engineered
interleukin-2 and drive expansion of antigen-specific regulatory T cells for
protection against autoimmune disease.
J Autoimmun. 2023;140:103125. PubMedAbstract available
August 2023
POYSTI S, Silojarvi S, Brodnicki TC, Catterall T, et al Gut dysbiosis promotes islet-autoimmunity by increasing T-cell attraction in
islets via CXCL10 chemokine.
J Autoimmun. 2023;140:103090. PubMedAbstract available